The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...
In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive ...
The US drug wholesaling industry is stable post-opioid settlement, with focus shifting to fund management and pharmacy benefit managers. The Big Three wholesalers are financially strong, expanding ...
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures ...
A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
Medicare negotiation applies first to Part D retail drugs and later to Part B physician-administered agents, with negotiated maximum fair prices phased in beginning January 1, 2026. The $2,100 annual ...
Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor ...
In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...
A conservative 3% trend means a $100 billion Medicare Advantage book could face a $3 billion shortfall. Even before the Final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results